Archive | August, 2021

Hot Longevity Mandate: China-Based Corporate Venture Fund

10 Aug

The corporate venture fund is a sector-exclusive life sciences venture and growth equity fund focused on Asia, particularly China. Originally established in 2008 as a corporate venture subsidiary of a Big Pharma, the firm has since spun off and operates as an independent investment firm with offices in China and the US. The fund currently has ~$4.5B AUM and is investing from their fifth fund, a $750M fund that was closed in 2019. The firm is stage agnostic, investing as early as seed, growth, and up to pre-IPO opportunities. The firm has a team of investment professionals all with healthcare background. Investment size is USD $5-25 million per company. The firm prefers to lead or co-lead a financing round. With both USD and RMB funds, the firm focuses on China but also considers opportunities from USA.

In life sciences, the firm is focused on therapeutics with an emphasis on oncology, metabolic disorders, cell therapy, and biologics, etc. The firm is also interested in medical devices and diagnostics. The firm is opportunistic to the indication and the phase of development and will consider products in pre-clinical up to NDA.

The firm is seeking experienced management teams that are going rapidly and emerging as market leaders. The firm is seeking companies developing technologies that are truly based on high quality science, but also aligned with the potential of attractive financial return. Because the firm focuses its activities in China, the firm will prefer companies outside of China to have a strong China angle. The firm typically requires a board seat or observation rights post investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

Hot AI Mandate: Japan-based VC with Big Pharma LPs Invests Globally in First-in-Class Therapeutics

9 Aug

A cross-border venture capital firm founded in 2014 is headquartered in Tokyo, Japan, with USA offices in Cambridge, MA and Seattle, WA. The firm recently closed its second fund at $95M. Its LPs includes some of the largest Japanese pharmaceutical companies. The firm has also launched a new life sciences incubator through which the firm seeks to nurture and advance early-stage therapeutic concepts and technologies with the goal of bringing them to a more mature stage of development. Typically, the firm makes an initial investment ranging from under $1 million to $3-6 million dependent on the company’s stage of development. The firm can allocate up to $16 million over the lifetime of a company. The firm invests in early-stage therapeutic companies worldwide.

The firm only invests in therapeutics, and are primarily focused on companies with preclinical or clinical assets. Within therapeutics, all modalities are of interest. The firm may invest up to 18 months prior to IND, however require that a company has a lead asset that has been characterized. The firm will consider opportunities in any indication area.

The firm invests in teams with experienced, highly motivated teams with a strong background in either life science research or industry. The firm only invests in companies with technology that has the potential to be first in class.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

Hot AI Mandate: Health System Subsidiary Make Strategic Investments in Technologies Related to Hospital Care

9 Aug

An investment group based in New York is a wholly-owned subsidiary of a health system. The firm engages in strategic investments across a wide variety of sectors to benefit the health system. The firm invests at a set pace with ~2 surgery centers being invested in per year and are currently looking to diversify their portfolio. The firm tends to invest in seed and pre-revenue rounds as their allocation size is on the smaller side, but is interested in revenue generating opportunities with smaller rounds. The firm is currently in the process of diversifying their portfolio and prefers investing in companies that are related to the health system in some way such as companies that the health system is a customer of, companies that have done clinical studies within the health system, etc.

The firm is particularly interested in technologies that can help them increase the quality of care, decrease the cost of care, and increase the access of services to populations which have been historically denied. Beyond that though, the firm is rather opportunistic within the healthcare IT, medical

The firm requires that companies have some sort of relationship with the hospital system or have the endorsement of the senior management of the health system.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

Hot AI Mandate: India-based VC Invests Globally in Life Sciences/AI Opportunities

9 Aug

Founded in 2011 and based in Mumbai, India, a venture capital firm makes Seed to Series B investments across several key sectors including healthcare, fintech, consumer, AI, and life science services. The firm manages $200 million, and is investing from its second fund. While IvyCap focuses on India, the firm is looking for opportunities worldwide and has recently made an investment in the USA.

The firm will consider a wide variety of life science opportunities. The firm’s past investments have included pharma supply chain, AI, and healthcare services.

The firm seeks a strong and experienced management team, with a focus on entrepreneurs from elite educational institutions. The firm focuses on India and has a strong connection with the Indian Institutes of Technology, but looks worldwide for novel technology breakthroughs to invest in. The firm has also launched a Unified Innovation and Entrepreneurship Platform to incubate new startups.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The Business of Biotech: The Moexa Perspective

5 Aug

By Rory McCann, Marketing Manager & Conference Producer, LSN

Every startup operates according to the strengths of its leaders and partners, making it essential for successful companies to be built on the diverse skill sets of their teams. Former Innovation Challenge (now Innovator’s Pitch Challenge) winner, Moexa is a shining example of unique experiences and diverse skills put to the test and passing.

Moexa Director and CEO, Anthony Desir has had a successful career in finance and business development before leading the multi-national drug research and development company, and took the time to share his RESI experience, as well as the tools he’s utilized to lead Moexa and lessons he’s learned along the way. Listen to our conversation and sign up for RESI Partnering Week, September 13-17 to jumpstart your own early-stage fundraising journey. Early bird rates for RESI Partnering Week end Friday, August 6. Register today to save!

Early Bird Ends Tomorrow

5 Aug

By Caitlin Dolegowski, Marketing Specialist, LSN

RESI Partnering Week, September 13-17 early bird rates end tomorrow! Register by August 6 to save $50 on standard, premier, and bundle packages. RESI Partnering Week is a five-day virtual partnering experience designed to connect early-stage life science and healthcare startups with investors and strategic partners that are a fit for their product and stage of development.

RESI Partnering Week is unique because it features three events (Digital RESI, RESI AI, and RESI Longevity) that each use a match-based partnering platform designed to take the guesswork out of partnering because it enables users to filter attendees to meet with based on their fundraising needs. To learn more about the partnering platform, join us for a free fundraising bootcamp August 11 or August 18.

Additionally, RESI Partnering Week features conversations with entrepreneurs and investors around specific topics related to the early-stage fundraising ecosystem through expert panels and hosts the Innovator’s Pitch Challenge (IPC), providing opportunities for fundraising executives to pitch directly to a panel of relevant, active investors. IPC applications are accepted on a first-come-first-serve basis, so apply by August 20 to be considered!

Whether sourcing elite technology assets or seeking funding from a strategic partner who is a fit for your company, RESI Partnering Week is a one-stop shop to help you meet your needs. Learn more about what each event has to offer and sign up by August 6 to save!

RPW September 2021 Confirmed Investors
Confirmed RESI Investors Confirmed RESI AI Investors Confirmed RESI Longevity Investors

As of August 5

Tech Hubs & RESI Partnering Week

5 Aug

By Elizabeth Murphy, Manager of Business Development, LSN

Life Science Nation (LSN) recognizes how Tech Hubs – global incubators and accelerators – are impact entrepreneurs for success, and in turn, close collaboration with these groups and their constituent companies add a value to partnering events, like RESI Partnering Week. Over the last year, LSN has hosted Tech Hubs such as AZ Bio, Women in Bio, and Lyonbiopole and their constituents have had the opportunity to meet the investors and strategic partners who are part of the RESI community. Get to know these Tech Hubs and check out the opportunities available to constituents of those participating in the RESI Partnering Week Global Tech Hub Gathering:

We are currently offering two programs to accelerate Tech Hub involvement and help fund constituents:

  • 50% discount on any RESI conference registration for early-stage constituent companies from participating Tech Hubs
  • Group Fundraising Package ($1,500 per company) for Tech Hubs including:
  • 3-month access to the Investor Database
  • Registration at RESI
  • Participation in the Innovator’s Pitch Challenge

The Arizona Bioindustry Association (AZBio)

AZBio Member Organizations in the fields of business, research and education, health care delivery, economic development, government, and other professions involved in the biosciences are the key drivers of the growth of Arizona’s life science sector. As the unified voice of our industry in Arizona, AZBio strives to make Arizona a place where bioscience organizations can grow and succeed. AZBio works nationally and globally with the Advanced Medical Technology Association (AdvaMed), the Biotechnology Innovation Organization (BIO), the Medical Device Manufacturers Association (MDMA), the Pharmaceutical Research and Manufacturers of America (PhRMA), and leading patient advocacy organizations. Through these relationships, AZBio has access to information, contacts, resources, cost saving programs, and the global bioscience and MedTech community.

Lyonbiopole

As a Cluster, Lyonbiopole is the gateway to healthcare innovation in the Auvergne-Rhône-Alpes region. It’s supporting ambitious projects and innovative companies in the healthcare and life sciences sectors. Its aim is to help innovators develop new technologies, products, and services in a push toward a more personalized medicine and better treatments for patients. Its four strategic areas include human medicine, veterinary medicine, in vitro diagnostics, and medical devices and medical technologies.

Women in Bio (WIB)

Women in Bio is an incubator of North American women in the life science industry. WIB aims to help women achieve the highest levels of leadership, influence and decision-making that they desire. As WIB grows its membership, its activities, and its geographic spread, it is rapidly becoming a leading authority and organization for women in the life sciences. Their focuses are on education, mentoring and networking, and on creating opportunities for leadership that can help advance careers. In the past WIB has been an incredible addition to the RESI conferences, sending esteemed life science women entrepreneurs to connect with investors specific to their indication. We look forward to working with them back again at future RESI conferences.

If your Tech Hub is looking for ways to add value to fundraising constituents, connect with the LSN business development team to see which offerings best fit your needs and the companies in your community. LSN shares the mission of global Tech Hubs in seeing promising technologies advance from the lab to the clinic, and into the hands of providers and their patients.

Want to learn more? The business development team at Life Science Nation is available to answer questions and share additional details to help you meet your partnership goals!
International & MA (USA) West Coast (USA) East Coast (USA) Midwest (USA) & Canada
Greg Mannix
Vice President International Business Development
Book a Meeting!		 Candice He
 Global Investment Strategist
Book a Meeting!		 Elizabeth Murphy
Manager of Business Development
Book a Meeting!		 Antoinette Lowre
Manager of Business Development
Book a Meeting!
← Older Entries
Newer Entries →